1. Introduction

Regulatory reform for consent simplification refers to the process of modernising legal and administrative requirements governing consent so that individuals can understand, provide, withdraw, and manage their consent without unnecessary procedural complexity.

In biotechnology, genetic research, clinical trials, medical treatment, reproductive technologies, genomic databases, and biomedical innovation, consent is a fundamental legal safeguard. It protects individual autonomy, bodily integrity, privacy, dignity, and the right to make informed decisions.

However, traditional consent procedures often involve lengthy documentation, complicated legal terminology, repetitive signatures, multiple approval stages, and unclear explanations of risks. These difficulties can discourage research participation, delay clinical investigations, and increase administrative costs.

The objective of regulatory simplification is therefore not to weaken informed consent but to make it more understandable, accessible, transparent, and legally reliable.

Central legal principle: Simplification must reduce unnecessary formalities without eliminating the essential elements of voluntary, informed, specific, and revocable consent.

2. Meaning and Scope of Consent Simplification

Consent simplification involves reforming legislation, regulations, institutional procedures, and administrative practices to make consent easier to obtain and manage.

Its principal dimensions include:

Simplified documentation: Replacing unnecessarily lengthy forms with clear and understandable documents.

Digital consent: Permitting electronic signatures and digital consent records where legally appropriate.

Plain-language explanations: Presenting scientific and medical information in language that participants can understand.

Standardised procedures: Developing common consent requirements across research institutions and healthcare organisations.

Tiered consent: Allowing participants to make separate choices concerning different research activities.

Dynamic consent: Enabling participants to update their preferences as research purposes or data uses change.

Withdrawal mechanisms: Establishing accessible procedures for withdrawing consent.

Protection of vulnerable persons: Maintaining additional safeguards for children, persons with impaired decision-making capacity, and other vulnerable research participants.

3. Legal Framework in Morocco

Morocco provides an important framework for examining consent simplification in biotechnology and biomedical research.

A. Law No. 28-13 on the Protection of Persons Participating in Biomedical Research (2015)

Law No. 28-13 is central to the regulation of informed consent in Moroccan biomedical research.

Article 3 establishes important principles, including:

Respect for human life, health, physical and psychological integrity.

Protection of human dignity and privacy.

Voluntary participation in biomedical research.

Express and informed consent.

Autonomy of the research participant.

Article 4 requires free, informed, and express consent before biomedical research involving a person. Participants must receive oral and written explanations in a language they understand. Information must cover the research objectives, methodology, duration, foreseeable risks, expected benefits, and available medical alternatives.

It also recognises the possibility of assistance from a person chosen by the participant to understand the information.

Ma Loi+1

Legal significance: Regulatory simplification in Morocco should make these requirements easier to fulfil without removing the statutory obligation to provide meaningful information.

B. Law No. 09-08 on Personal Data Protection

Morocco's Law No. 09-08 regulates the processing of personal data.

It is particularly relevant when consent simplification involves:

Genetic information.

Electronic medical records.

Digital research databases.

Health-related personal information.

Sharing biomedical data between research institutions.

Article 21 addresses express consent and certain legal exceptions to consent, subject to the applicable statutory conditions and CNDP authorisation requirements. Article 22 establishes specific provisions for certain health-data processing activities.

Simplifying consent for biomedical data must therefore be distinguished from eliminating the legal requirements governing sensitive personal information.

BDJ

C. Constitutional and Human Rights Principles

Consent reform should respect fundamental rights, particularly:

Human dignity.

Physical and psychological integrity.

Privacy.

Personal autonomy.

Equality and non-discrimination.

Access to appropriate healthcare.

The reform of consent procedures must ensure that administrative efficiency does not become a justification for coercion, uninformed participation, or exploitation of vulnerable populations.

4. Major Areas of Regulatory Reform

A. Simplification of Informed Consent Forms

Traditional biomedical consent documents can be lengthy and difficult to understand.

Regulatory authorities can introduce standardised forms containing:

The purpose of the research.

The procedures involved.

Potential risks and benefits.

Data collection and storage arrangements.

Confidentiality protections.

Compensation and treatment for research-related injury, where applicable.

Withdrawal rights.

Contact details for complaints and further information.

The forms should use plain language and explain scientific terminology.

In Morocco, such standardisation should remain consistent with the information requirements of Article 4 of Law No. 28-13.

B. Digital and Electronic Consent

Digital consent allows participants to review research information and record their decisions electronically.

Possible regulatory reforms include:

Electronic consent signatures.

Secure identity verification.

Digital consent timestamps.

Electronic records of consent withdrawal.

Secure storage of consent documentation.

Remote consent procedures for eligible research participants.

However, digital consent should not become compulsory where participants lack internet access, digital literacy, or appropriate devices.

Alternative paper-based and assisted procedures must remain available.

C. Tiered Consent Mechanisms

Tiered consent allows individuals to select different levels of participation.

For example, a person participating in a genetic research project could separately decide whether to permit:

Use of samples for the original research.

Future research involving related scientific questions.

Storage of biological samples.

Sharing of coded research data.

Contact for future research opportunities.

This model avoids forcing participants to accept every proposed use as a single package.

D. Dynamic Consent

Dynamic consent is a system through which participants can review and update their consent preferences over time.

For example, a participant who initially agrees to a genetic study may later be asked whether their coded data can be used in another research project.

A digital platform can communicate the new research purpose and record the participant's choice.

Dynamic consent is particularly useful in:

Genomic research.

Long-term clinical studies.

Biobanking.

Precision medicine.

Artificial intelligence-assisted medical research.

Nevertheless, dynamic consent cannot automatically legitimise every subsequent use of data. Researchers must still comply with applicable legal requirements, research ethics approvals, and restrictions on secondary processing.

E. Simplification for Vulnerable Participants

Regulatory simplification must not weaken protections for vulnerable persons.

Special procedures should be available for:

Children and adolescents.

Persons with impaired decision-making capacity.

Patients in emergency situations.

Economically disadvantaged participants.

Persons with limited literacy.

Participants who do not understand the language used in research documents.

Informed consent must remain voluntary. Where legally required, representative authorisation and the participant's own assent or involvement must also be obtained.

Morocco's Article 4 provides a specific framework for situations in which a person's clinical condition prevents prior consent, including family-member consent and subsequent information and consent requirements.

5. Important Judicial Decisions and Case Laws

Although Moroccan Law No. 28-13 provides the statutory framework, the following international judicial decisions offer useful comparative principles for reforming consent procedures. They should not be treated as binding Moroccan precedents.

1. V.C. v. Slovakia (2011), Application No. 18968/07

Highly relevant

Facts: A young Roma woman underwent sterilisation during childbirth. The medical staff obtained her signature shortly before the procedure, when she was experiencing labour pain and had not been adequately informed about the procedure and alternatives.

Judgment: The European Court of Human Rights found violations of Articles 3 and 8 of the European Convention on Human Rights.

Legal principles:

Consent must be genuinely voluntary.

Medical information must be understandable.

A signature alone does not establish informed consent.

Medical professionals must respect patient autonomy.

Vulnerable patients require effective safeguards.

Relevance to regulatory reform: Simplifying consent documents must not turn consent into a mere signature-collection exercise. The procedure must enable individuals to understand and freely decide.

HUDOC+1

2. Pretty v. United Kingdom (2002), Application No. 2346/02

Facts: The case concerned a woman suffering from a progressive and incurable illness who challenged aspects of the legal framework governing assisted suicide.

Judgment: The European Court examined the relationship between personal autonomy, physical integrity, and the right to respect for private life.

Legal principles:

Personal autonomy is an important dimension of private life.

Individual decisions concerning bodily integrity deserve legal recognition.

Medical decision-making must respect human dignity.

Relevance: Consent reform should protect the individual's ability to make independent healthcare decisions rather than prioritising administrative convenience.

3. Glass v. United Kingdom (2004), Application No. 61827/00

Facts: The dispute involved medical treatment administered to a child despite disagreement between the child's mother and medical professionals.

Judgment: The European Court found a violation of Article 8 because the treatment had been administered without the necessary judicial resolution of the dispute.

Legal principles:

Medical intervention must respect private and family life.

Disagreements concerning consent cannot simply be disregarded.

Legal safeguards are necessary where representatives and healthcare professionals disagree.

Relevance: Simplified consent procedures must include clear mechanisms for resolving disputes involving children, guardians, and medical institutions.

4. Spivak v. Ukraine (Application No. 21180/15)

Legal significance: The judgment discusses the principles governing medical consent and refers to the distinction between express and implied consent.

It recognises that the appropriate form of consent depends on the nature of the intervention. Routine medical acts may not always require the same formalities as invasive procedures.

Legal principles:

Consent requirements should be proportionate to the intervention.

Express consent may be written or verbal, depending on the circumstances.

More serious procedures may require stronger consent safeguards.

Consent must remain voluntary and capable of withdrawal, subject to applicable professional obligations.

Relevance: This decision supports risk-based regulatory reform rather than imposing identical documentation requirements on every medical activity.

Bailii

5. Jehovah's Witnesses of Moscow v. Russia (2010), Application No. 302/02

Legal principles: The Court's discussion of medical autonomy recognises the importance of respecting an individual's freedom to make healthcare decisions, including decisions concerning medical treatment.

Relevance: Consent simplification must preserve the right to refuse treatment and should not allow institutions to substitute administrative procedures for individual choice.

6. Regulatory Challenges in Morocco

Several challenges may arise when implementing simplified consent procedures in Morocco.

A. Language and Literacy Barriers

Consent documents should be available in accessible language appropriate to the participant.

In Morocco, Arabic, Amazigh, and other languages may be relevant depending on the participant population and research setting.

A translated document should communicate the same legal and scientific information as the original.

B. Digital Privacy and Cybersecurity

Electronic consent systems create risks involving unauthorised access, data manipulation, identity theft, and disclosure of genetic information.

Regulatory authorities should require:

Secure authentication.

Encryption.

Access controls.

Audit trails.

Data minimisation.

Secure retention and deletion policies.

C. Institutional Accountability

Hospitals, universities, biotechnology companies, and research organisations should be responsible for ensuring that consent procedures comply with applicable law.

Institutional review mechanisms should examine whether consent was genuinely informed rather than merely documented.

D. Commercial Use of Biological Samples

Particular care is required where biological samples collected for academic research are later used in commercial biotechnology development.

Participants should receive clear information about relevant future uses, commercialisation arrangements where applicable, and the limits of confidentiality and withdrawal.

7. Proposed Regulatory Reforms for Morocco

Morocco could consider the following measures to modernise its biomedical consent framework.

1. Standardised national consent templates

Develop standard templates under Law No. 28-13 for clinical trials, genetic testing, biobanking, and other categories of biomedical research.

2. Risk-based consent requirements

Differentiate between low-risk research, invasive procedures, and high-risk genetic or reproductive interventions.

Risk-based simplification should never remove legally required consent.

3. Electronic consent recognition

Establish clear rules for electronic consent, identity verification, authentication, record retention, and evidentiary reliability.

4. Tiered and dynamic consent

Develop legally controlled mechanisms allowing participants to choose among permitted research uses and update their preferences.

5. Strong withdrawal mechanisms

Provide accessible withdrawal procedures and explain the practical and legal limitations of withdrawing data or samples already incorporated into completed research or irreversibly anonymised datasets.

6. Independent ethics oversight

Require ethics committees to examine consent materials, participant comprehension, vulnerable-person protections, and proposed secondary uses.

7. Researcher accountability

Introduce institutional audits, documentation requirements, training, and proportionate sanctions for obtaining consent through coercion, deception, or material misrepresentation.

8. Public awareness programmes

Promote public understanding of biomedical research, genetic information, privacy rights, and voluntary participation.

8. International Standards and Regulatory Principles

Moroccan reform can also draw upon internationally recognised bioethics principles.

UNESCO Universal Declaration on Bioethics and Human Rights (2005), Article 6: Establishes free and informed consent as a fundamental requirement for medical interventions and scientific research.

Article 5: Protects individual autonomy and requires special measures for persons unable to exercise it.

Article 7: Addresses the protection of persons who lack the capacity to consent.

Council of Europe Convention on Human Rights and Biomedicine (Oviedo Convention), Article 5: Requires free and informed consent and recognises the right to withdraw it.

These standards provide useful comparative guidance for developing transparent and participant-centred consent procedures.

9. Recommendations for Legislative Development

A comprehensive Moroccan reform programme should incorporate five priorities:

Amend or supplement implementing regulations under Law No. 28-13 to clarify simplified consent procedures.

Recognise appropriately authenticated electronic consent records.

Establish national standards for plain-language and multilingual consent documentation.

Create specific regulatory safeguards for genetic databases, biobanks, and secondary research.

Strengthen independent monitoring, complaints procedures, and remedies for violations of consent rights.

10. Conclusion

Regulatory reform for consent simplification is an important element of modern biotechnology governance. It seeks to reconcile scientific development, administrative efficiency, individual autonomy, and human rights protection.

In Morocco, Law No. 28-13 and Law No. 09-08 provide significant foundations for this reform. Their implementation can be improved through standardised documentation, digital consent systems, tiered consent, dynamic consent, and stronger institutional accountability.

The decisions in V.C. v. Slovakia, Pretty v. United Kingdom, Glass v. United Kingdom, and Spivak v. Ukraine demonstrate that consent is fundamentally about individual autonomy and meaningful decision-making, not merely obtaining a signature.

An important research qualification: The cases discussed above are comparative international jurisprudence. I have not identified a verified Moroccan appellate judgment directly establishing a doctrine of consent simplification. They should therefore be used as comparative authorities rather than presented as Moroccan precedents.

Ultimately, the purpose of regulatory simplification should be to make consent easier to understand and exercise while ensuring that no individual loses control over decisions concerning their body, biological samples, medical treatment, or personal genetic information.

11. Important Legal References

Moroccan Law No. 28-13 (2015), Protection of Persons Participating in Biomedical Research.

Moroccan Law No. 09-08 (2009), Protection of Individuals with Regard to Personal Data Processing.

UNESCO Universal Declaration on Bioethics and Human Rights, 2005.

European Convention on Human Rights, Articles 3 and 8.

V.C. v. Slovakia (2011).

Pretty v. United Kingdom (2002).

Glass v. United Kingdom (2004).

Spivak v. Ukraine (2025).

Primary research sources:

Moroccan Law No. 28-13 – Article 4.

Moroccan Law No. 09-08.

European Court of Human Rights – V.C. v. Slovakia.